|
Newsletter June 2022
|
|
|
|
Dear partners and colleagues,
As we rapidly approach the middle of 2022, we wanted to take the opportunity to share progress updates and a snapshot of our journey with you.
Below, you will find some updates from us at GAP-f and our partners.
We would like to reiterate our gratitude to our members and partners who continue to provide the guidance and nurturing of this initiative since it was launched, enabling growth and vision going forward so that we can be together, stronger, for kids.
|
|
|
Launch of GAP-f Strategy
GAP-f, together with its partners, launched its 2022-2024 strategy on March 1 through an online event. The strategy builds from the work undertaken to date by the network of leading partners, both individually and collectively, through GAP-f. With this new strategy, we are excited to expand our footprint into a broader set of diseases to bring us closer to our vision of all children having equitable access to the medicines they need. Read the strategy here and hear what our partners have to say about the need for ensuring access to better formulations here.
|
|
|
|
|
Unitaid and ELMA provide support to GAP-f
The ELMA Foundation and Unitaid, who together funded the GAP-f Secretariat costs during Phase 1 of GAP-f work (2019-2021), are making a joint investment for Phase 2 that comprises sub-award support to key GAP-f partners.
Over Phase 2, GAP-f will leverage its position to enable a more integrated approach across paediatric
therapeutic areas, develop a widely accepted paediatric drug prioritization framework, introduce new
technologies, create a robust data system to track paediatric R&D, and pilot funding mechanisms to
support the product lifecycle from development to delivery.
|
|
|
|
|
Save the date! Upcoming GAP-f webinar
GAP-f will continue with its #BetterMeds4Kids quarterly webinar series covering a range of paediatric-focused topics during the course of 2022. The Clinical Research Working Group will host the first webinar for 2022, on July 6th entitled Enhanced use of data to monitor safety and effectiveness of paediatric medicines and will discuss the development of a Paediatric Data Hub which aims to use innovative methods and real-world data to monitor the safety and effectiveness of new paediatric medicines.
Register here for the event.
|
|
|
|
|
Paediatric DTG Implementation Considerations for National Programmes now available
Experiences from pDTG early adopter countries have highlighted some implementation and administration complexities surrounding pDTG’s 90-count bottles. The challenges are primarily associated with dispensing pDTG to children weighing less than 10kg, because the 90-count bottle equates to a four- to six-month supply for children who start pDTG at 3kg to 5.9kg and a two-month supply for children 6kg to 9.9kg. To ensure children are transitioned to pDTG safely and effectively, the GAP-f pDTG Task Team has put forth some considerations for national HIV programmes, implementing partners, and service providers. The document is available in English, French, Kiswahili, Portuguese and Spanish here. Please share with colleagues working with national HIV programmes.
|
|
|
|
|
Publication on the development of a tool to assess the appropriateness of essential medicines included in the EMLc
This article describes the development and application of a paediatric Quality Target Product Profile (pQTPP) tool developed by WHO, to retrospectively evaluate the paediatric age-appropriateness of formulations on the EMLc and identify potential formulation gaps which will inform the review of the EMLc in 2023. The pQTTP tool may also be applied in the future to national lists and prospectively when designing new paediatric formulations.
|
|
|
|
|
|
Paediatric ARV dosing dashboard is now live
The Paediatric ARV dosing dashboard is live on WHO’s website! The aim of the dashboard is to support health care workers, researchers and policy makers in decisions around HIV antiretroviral (ARV) treatment dosing for children. It includes a dosing tool to assist in selecting the correct dose for infants, children and adolescents less than 18 years of age, background information to support WHO paediatric weight-band dosing recommendations for ARV drugs, and a tool for researchers who may want to investigate various ARV dosages and calculate the expected drug exposure
in children.
We invite you to view the tool here and circulate it widely amongst your network.
|
|
|
|
|
Application period for the 2023 update of the Essential Medicines List for Children is now open
The application period for the 2023 update of the WHO Model Lists of Essential Medicines and Essential Medicines for Children is now open. The deadline for the submission of applications is 18h00 UTC on Friday 16 December 2022. Applications received will be considered by the WHO Expert Committee on the Selection and Use of Essential Medicines at its next meeting in Geneva, scheduled for 24 to 28 April 2023. Updated information for applicants, including details of the required information to be included in submissions, is available here.
|
|
|
|
The PATA Summit will take place 21 - 23rd November 2022. This will again be a hybrid summit, with in-person satellite meetings in several countries that join virtually for a regional programme. Please also see the last PATA 2021 Summit Report.
PATA REAL is a quarterly webinar series for the PATA network that offers real cases that front-line health providers see during routine clinical care. The objective of the webinars is to offer health providers a platform for case-based practical learning to improve paediatric and adolescent HIV service delivery. PATA REAL webinars for 2022 will take place on August 18 and November 22. Please register here and here.
|
|
|
|
Highlights from Penta-ID Network (PIM) meeting
The Penta-ID Network Meeting took place in Sorrento, Italy 28-30 April 2022. Click here to read highlights from the meeting.
|
|
|
|
The Goodman Pediatric Formulations Centre
The Goodman Pediatric Formulations Centre is proud to inform you of the publication of the commentary entitled Time for a regulatory framework for pediatric medications in Canada in the Canadian Medical Association Journal (CMAJ). This work was a collective effort, with the hopes of helping shape policy to improve access to pediatric formulations. Read the article here.
|
|
|
|
|
Unsubscribe
|
